Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ALGS
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Gregory Martinez | 325,537 | 5.2% | SCHEDULE 13G ↗ |
| Nov 13, 2026 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Parkman Healthcare Partners Holdings GP LLC | 325,537 | 5.2% | SCHEDULE 13G ↗ |
| Nov 13, 2026 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Parkman Healthcare Partners Holdings LP | 325,537 | 5.2% | SCHEDULE 13G ↗ |
| Nov 13, 2026 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Parkman Healthcare Partners LLC | 325,537 | 5.2% | SCHEDULE 13G ↗ |
| Jun 24, 2026 | SCHEDULE 13D | ALGS Aligos Therapeutics, Inc. | Lawrence M. Blatt | 316,228 | 5.6% | SCHEDULE 13D ↗ |
| May 15, 2026 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Lawrence M. Blatt | 286,213 | 5.1% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Woodline Partners LP | 239,362 | 4.4% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Woodline Partners LP | 289,169 | 5.4% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Sio Capital Management, LLC | 335,937 | 5.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Woodline Partners LP | 468,199 | 8.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Woodline Partners LP | 518,300 | 9.8% | SCHEDULE 13G/A ↗ |
| Aug 13, 2025 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Sio Capital Management, LLC | 355,937 | 5.5% | SCHEDULE 13G ↗ |
| Aug 12, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Phillip Gross | 210,000 | 3.9% | SCHEDULE 13G/A ↗ |
| Aug 12, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Robert Atchinson | 210,000 | 3.9% | SCHEDULE 13G/A ↗ |
| Aug 12, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Adage Capital Management, L.P. | 210,000 | 3.9% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Anand Parekh | 530,000 | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Alyeska Fund GP, LLC | 530,000 | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Alyeska Investment Group, L.P. | 530,000 | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | EcoR1 Capital Fund Qualified, L.P. | 199,036 | 3.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Oleg Nodelman | 210,634 | 3.9% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | EcoR1 Capital, LLC | 210,634 | 3.9% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G | ALGS Aligos Therapeutics, Inc. | Woodline Partners LP | 315,383 | 5.2% | SCHEDULE 13G ↗ |
| Mar 12, 2025 | SCHEDULE 13D/A (amended) | ALGS Aligos Therapeutics, Inc. | Lawrence M. Blatt, Ph.D. | 175,509 | 3.2% | SCHEDULE 13D/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Steven Boyd | 188,438 | 5.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Armistice Capital, LLC | 188,438 | 5.0% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Phillip Gross | 325,000 | 9.4% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Robert Atchinson | 325,000 | 9.4% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | ALGS Aligos Therapeutics, Inc. | Adage Capital Management, L.P. | 325,000 | 9.4% | SCHEDULE 13G/A ↗ |
28 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:46 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances